Presentation is loading. Please wait.

Presentation is loading. Please wait.

Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,

Similar presentations


Presentation on theme: "Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,"— Presentation transcript:

1 Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum, Peter Senior

2 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association SCREEN regularly with random urine albumin creatinine ratio (ACR) and serum creatinine for estimated glomerular filtration rate (eGFR) DIAGNOSE with repeat confirmed ACR ≥2.0 mg/mmol and/or eGFR <60 mL/min DELAY onset and/or progression with glycemic and blood pressure control and ACE-inhibitor or Angiotensin Receptor Blocker (ARB) PREVENT complications with “sick day management” counselling and referral when appropriate 2013 Chronic Kidney Disease (CKD) Checklist

3 Patients with DM 6-12X more likely to be hospitalized for CKD or End-stage renal disease (ESRD) Public Health Agency of Canada (August 2011); using 2008/09 data from the Canadian Chronic Disease Surveillance System (Public Health Agency of Canada).

4 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Diabetes is #1 Cause of New Cases of ESRD Public Health Agency of Canada (August 2011); using 2008/09 data from the Canadian Chronic Disease Surveillance System (Public Health Agency of Canada).

5 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CKD in Diabetes ACR ≥2.0 mg/mmol and / or eGFR <60 mL/min 2013

6 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Diabetic Nephropathy “ Progressive increase in proteinuria in people with longstanding diabetes, followed by declining function which can eventually lead to End-Stage Renal Disease (ESRD)”

7 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Stages of Diabetic Nephropathy Note: change in definition of microalbuminuria ACR ≥2.0 mg/mmol 2013

8 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

9 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Screening and Diagnosis of CKD in Diabetes

10 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

11 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Beware of Transient Albuminuria

12 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

13 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

14 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 2013

15 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

16 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

17 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 2

18 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Beware of Other Causes of CKD

19 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association When to Consider Other Causes of CKD

20 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 2

21 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Care Gap Still Exists for Screening Canadian Institute of Health Information – Diabetes Care Gap 2009

22 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Optimal glycemic control in type 1 and type 2 diabetes has been shown to reduce the development and progression of nephropathy Prevention of Diabetic Nephropathy

23 The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986. 34% RRR (p<0.04) 43% RRR (p=0.001) 56% RRR (p=0.01) Primary PreventionSecondary Intervention Solid line = risk of developing microalbuminuria Dashed line = risk of developing macroalbuminuria DCCT: Reduction in Albuminuria RRR = relative risk reduction CI = confidence interval guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

24 deBoer IH et al. Arch Intern Med 2011;171(5):412-420. HR 1.92 (p<0.05) HR 0.64 (95% CI 0.40-1.02) Return to normoalbuminuria Macroalbuminuria HR = hazard ratio CI = confidence interval guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association EDIC: Continued Reduction in Albuminuria

25 EDIC: Early Glycemic Control Reduces Long-term Risk of Impaired GFR Risk reduction with intensive therapy 50% (95% CI 18-69; p=0.006) DCCT/EDIC Research Group. N Engl J Med 2011;365:2366-76.

26 After median 8.5 years post-trial follow-up Aggregate Endpoint 19972007 Any diabetes related endpoint RRR: 12%9% P: 0.029 0.040 Microvascular disease RRR: 25%24% P: 0.00990.001 Myocardial infarction RRR: 16%15% P: 0.0520.014 All-cause mortality RRR: 6%13% P: 0.440.007 Holman R, et al. N Engl J Med 2008;359. UKPDS: Post-trial Monitoring “Legacy Effect” guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

27 New/worsening nephropathy, retinopathy 66 Cumulative incidence (%) Follow-up (months) HR 0.86 (0.77-0.97) p = 0.01 Standard control Intensive control 25 20 15 10 5 0 06121824303642485460 Adapted from: ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72. ADVANCE Collaborative Group. N Engl J Med 2008;358:24. ADVANCE: Primary Microvascular Outcomes

28 Reducing Progression of Diabetic Nephropathy Optimal glycemic control (as shown) Optimal blood pressure control ACE-inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

29 ACE-inhibitor in T1DM with MAU Reduces Progression to Clinical Proteinuria Laffel LM et al. Am J Med 1995;99(5):497-504. Months of Therapy Proportion with Event guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

30 Lewis EJ et al. N Engl J Med 1993;329:1456-62. ACE-inhibitor in T1DM with Macroalbuminuria Reduces Renal Outcomes guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

31 ARB in T2DM with MAU reduces progression Parving et al. N Engl J Med 2001;345:870-8 Primary endpoint: Time to onset of diabetic nephropathy* (n=590) *defined by persistent albuminuria in overnight specimens, with urinary albumin excretion rate <200 μg/min and ≥30% higher than baseline level Placebo Irbesartan 150mg Irbesartan 300mg guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

32 Brenner et al. N Engl J Med 2001;345:861-9 Cumulative % of patients with event Months 240123648 Placebo Losartan Risk reduction = 16% p=0.02 0 10 20 30 40 50 Primary endpoint: Time to doubling of serum creatinine, ESRD, or death (n=1513) ARB in T2DM with Macroalbuminuria Reduces Renal Outcomes guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

33 Lewis et al. N Engl J Med 2001;345:851-60 Primary endpoint: Time to doubling of serum creatinine, ESRD, or death (n=1,715) Patients (%) 0 61218243036424854 Follow-up (mo) 60 0 10 20 30 40 50 60 70 Irbesartan Amlodipine Placebo RRR 20% p=0.02 p=NS RRR 23% p=0.006 ARB in T2DM with Macroalbuminuria Reduces Renal Outcomes

34 Safe use of treatments in kidney disease…..

35 Check serum K + and Cr – Baseline – Within 1-2 weeks of initiation or titration – During acute illness If K + becomes elevated or Cr >30% increase Review therapy Recheck serum K + and Cr Practical Tips: Potassium (K+) and Creatinine (Cr) guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

36 Mild to moderate stable hyperkalemia – Counsel on a low potassium diet – If persistent, consider adding non-potassium sparing diuretics and/or oral sodium bicarbonate (in those with metabolic acidosis) – Consider temporarily holding or discontinuing ACEi, ARB or Direct Renin Inhibitor (DRI) Severe hyperkalemia – Hold or discontinue ACEi, ARB or DRI – Emergency management strategies guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Practical Tips: Potassium (K+) and Creatinine (Cr)

37 Counsel all Patients About Sick Day Medication List 2013

38 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association See CPG Appendix 6 for therapeutic considerations for renal impairment 2013

39 Chronic, progressive loss of kidney function ACR persistently >60 mg/mmol eGFR <30 mL/min Unable to remain on renal-protective therapies due to adverse effects such as hyperkalemia or a >30% increase in serum Cr within 3 months of starting ACEi or ARB Unable to achieve target BP (could be referred to any specialist in hypertension) When to Refer….. guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

40 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 1.In adults, screening for CKD in diabetes should be conducted using a random urine ACR and a serum creatinine converted into an eGFR [Grade D, Consensus]. Screening should commence at diagnosis of diabetes in individuals with type 2 diabetes and 5 years after diagnosis in adults with type 1 diabetes and repeated yearly thereafter. Recommendation 1: Screening

41 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association A diagnosis of chronic kidney disease should be made in patients with a random urine ACR ≥2.0 mg/mmol and/or an eGFR<60 mL/min on at least two out of three samples over a three month period [Grade D, Consensus]. 2013 Recommendation 1: Screening (continued)

42 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Recommendation 2: Vascular Protection 2.All patients with diabetes and chronic kidney disease should receive a comprehensive, multifaceted approach to reduce cardiovascular risk (see Vascular Protection, CPG Chapter 22) [Grade A, Level 1A].

43 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Recommendation 3: Treatment 3.Adults with diabetes and CKD with either hypertension or albuminuria should receive an ACE inhibitor or an ARB to delay progression of CKD [Grade A, Level 1A for ACE-inhibitor use in type 1 and type 2 diabetes, and for ARB use in type 2 diabetes; Grade D, Consensus, for ARB use in type 1 diabetes].

44 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 4.People with diabetes on an ACE inhibitor or an ARB should have their serum creatinine and potassium levels checked at baseline and within 1 to 2 weeks of initiation or titration of therapy and during times of acute illness [Grade D, Consensus]. 5.Adults with diabetes and CKD should be given a “sick day” medication list that outlines which medications should be held during times of acute illness (see CPG Appendix) [Grade D, Consensus]. 2013 Recommendation 4 and 5

45 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Recommendation 6 6.Combination of agents that block the renin- angiotensin-aldosterone system (ACE-inhibitor, ARB, DRI) should not be routinely used in the management of diabetes and CKD [Grade A, Level 1]. 2013

46 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Recommendation 7: When to Refer 7.People with diabetes should be referred to a nephrologist or internist with an expertise in chronic kidney disease in the following situations: – Chronic, progressive loss of kidney function – ACR persistently >60 mg/mmol – eGFR<30 mL/min – Unable to remain on renal-protective therapies due to adverse effects such as hyperkalemia or a >30% increase in serum creatinine within 3 months of starting an ACE-inhibitor or ARB – Unable to achieve target BP (could be referred to any specialist in hypertension) [Grade D, Consensus]

47 CDA Clinical Practice Guidelines www.guidelines.diabetes.cawww.guidelines.diabetes.ca – for professionals 1-800-BANTING (226-8464) www.diabetes.ca www.diabetes.ca – for patients


Download ppt "Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,"

Similar presentations


Ads by Google